Search

1222498
1201004
1195994
393884
209802
ScimathUS
The South African Tuberculosis Vaccine Initiative will be offering a limited number of bursaries to cover the Registration Fees associated with the SciMathUS Program, a university preparation program which is offered by the Stellenbosch University...
Community Engagement
In March 2016 SATVI brought "Lienkie se Longe", a drama to raise awareness about TB, to the Worcester Easter Festival. The drama tells the story of Lienkie, whose lungs “talk with each other’ about their health and the health of Lienkie’s boyfriend...
Biomarker discovery offers hope for new TB vaccine development
A team of scientists from the University of Cape Town, Oxford University and the London School of Hygiene & Tropical Medicine have made a discovery that reveals how we can improve development of more effective vaccines against tuberculosis.
Community Engagement
In 2012 SATVI developed a drama production to promote awareness about TB vaccine clinical research, titled “Carina’s Choice” with learners from Worcester Secondary School as actors and UCT drama school students as mentors. A very successful roadshow...
Accredited UCT Research Centre
The South African Tuberculosis Vaccine Initiative (SATVI) is an accreditated Research Centre of the University of Cape Town.

News

Saturday, 18 November 2017
Progression from infection to Pulmonary Tuberculosis follows distinct timeline

SATVI researchers have uncovered a sequence of biological processes that occur in humans infected with the bacterium Mycobacterium tuberculosis as the infection progresses to pulmonary tuberculosis, according to new research published in the PLOS Pathogens Journal

Publication Date:
Friday, November 17, 2017 - 08:15
9 November 2017 Research Published: TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

Associate Professor Tom Scriba has collaborated with the authors of a research paper titled: "TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development" appearing in the Frontiers in Immunology Journal.

Publication Date:
Thursday, November 9, 2017 - 14:15
25 October 2017 Research Published Polyfunctional CD4+TCells as targets for vaccination

Associate Professor Tom Scriba has co authored a research paper titled "Polyfunctional CD4+T Cells as targets for Tuberculosis Vaccination" appearing in the Frontiers in Immunology Journal.

Publication Date:
Monday, November 6, 2017 - 14:45
5 October 2017 RESEARCH: Safety and Immunogenicity Immunogenicity of newborn MVA 85 A vaccination and selective delayed Bacille Calmette-Guerin for infants of HIV infected mothers: a Phase 2 Randomized Controlled Trial

SATVI authors Dr Elisa Nemes, Prof Mark Hatherill, Associate Prof Tom Scriba, Dr Michele Tameris, Humphrey Mulenga and Danelle Van As have published a research paper titled: "Safety and Immunogenicity of newborn MVA 85 A vaccination and selective delayed Bacille Calmette-Guerin for infants of HIV infected mothers: a Phase 2 randomized controlled trial" appearing in the Infectious Disease Journal (Oxford).

Publication Date:
Thursday, October 5, 2017 - 11:30

Pages